[HTML][HTML] MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine
D Medini, M Stella, J Wassil - Vaccine, 2015 - Elsevier
Recently approved in the EU, US, Australia, and Canada, 4CMenB (Bexsero®, GSK
Vaccines) is a multi-component meningococcal B (MenB) vaccine containing 3 surface …
Vaccines) is a multi-component meningococcal B (MenB) vaccine containing 3 surface …
A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
NG Martin, MD Snape - Expert review of vaccines, 2013 - Taylor & Francis
The first meningococcal vaccine with the potential to provide broad coverage against
serogroup B disease has recently been approved for use in Europe. This vaccine, multi …
serogroup B disease has recently been approved for use in Europe. This vaccine, multi …
[HTML][HTML] Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain …
G Frosi, A Biolchi, ML Sapio, F Rigat, S Gilchrist… - Vaccine, 2013 - Elsevier
Abstract Background 4CMenB (Bexsero), a vaccine developed against invasive
meningococcal disease caused by capsular group B strains (MenB), was recently licensed …
meningococcal disease caused by capsular group B strains (MenB), was recently licensed …
A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial
SL Block, L Szenborn, W Daly, T Jackowska… - Vaccine, 2015 - Elsevier
Background A meningococcal vaccine protective against all major disease-associated
serogroups (A, B, C, W and Y) is an unmet public health need. In this phase 2 observer …
serogroups (A, B, C, W and Y) is an unmet public health need. In this phase 2 observer …
[HTML][HTML] Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults
T Nolan, M O'Ryan, J Wassil, V Abitbol, P Dull - Vaccine, 2015 - Elsevier
Vaccination programs employing capsular-based meningococcal vaccines have proved
successful in a variety of settings globally since first introduced over 40 years ago. Similar …
successful in a variety of settings globally since first introduced over 40 years ago. Similar …
Translating meningococcal serogroup B vaccines for healthcare professionals
MAP Safadi, F Martinon-Torres, L Serra… - Expert Review of …, 2021 - Taylor & Francis
Introduction Vaccination is an effective strategy to combat invasive meningococcal disease
(IMD). Vaccines against the major disease-causing meningococcal serogroups are …
(IMD). Vaccines against the major disease-causing meningococcal serogroups are …
The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy
CS Rollier, C Dold, L Marsay… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Capsular group B meningococcal disease is a leading cause of childhood
meningitis and septicaemia. Up to 10% of sufferers die, and sequelae remain in> 30% of …
meningitis and septicaemia. Up to 10% of sufferers die, and sequelae remain in> 30% of …
Fighting Neisseria meningitidis: past and current vaccination strategies
G Piccini, A Torelli, E Gianchecchi… - Expert review of …, 2016 - Taylor & Francis
Introduction: Neisseria meningitidis infections represent a serious health problem that can
lead to invasive meningococcal disease (IMD), a life-threatening condition associated with …
lead to invasive meningococcal disease (IMD), a life-threatening condition associated with …
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals—the example of serogroup B meningococcal infection
ED McIntosh, V Carey, D Toneatto… - Therapeutic …, 2015 - journals.sagepub.com
In countries with established programmes for vaccination of infants, toddlers and
adolescents with meningococcal conjugate vaccines, serogroup B invasive meningococcal …
adolescents with meningococcal conjugate vaccines, serogroup B invasive meningococcal …
Distribution of Neisseria meningitidis serogroup b (NmB) vaccine antigens in meningococcal disease causing isolates in the United States during 2009–2014, prior to …
HY Chang, J Vuong, F Hu, P Liberator, A Chen… - Journal of Infection, 2019 - Elsevier
Objectives Two Neisseria meningitidis serogroup B (NmB) vaccines are licensed in the
United States. To estimate their potential coverage, we examined the vaccine antigen …
United States. To estimate their potential coverage, we examined the vaccine antigen …